Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19323422 | PHARMACEUTICAL COMPOSITION FOR KERATOSIS AND USE THEREOF | September 2025 | March 2026 | Allow | 6 | 0 | 1 | Yes | No |
| 19299240 | COMBINATION THERAPY WITH CLK/DYRK INHIBITORS AND BCL2 INHIBITORS TO TREAT LEUKEMIA | August 2025 | February 2026 | Allow | 6 | 0 | 2 | Yes | No |
| 19295468 | INHIBITION OF GLIAL CELL ACTIVATION | August 2025 | January 2026 | Allow | 6 | 0 | 1 | Yes | No |
| 19210898 | PHARMACEUTICAL DOSAGE FORMS AND METHODS OF USE | May 2025 | January 2026 | Allow | 8 | 1 | 1 | Yes | No |
| 19182010 | COMPOUNDS AND COMBINATIONS THEREOF FOR TREATING NEUROLOGICAL AND PSYCHIATRIC CONDITIONS | April 2025 | November 2025 | Allow | 7 | 1 | 0 | Yes | No |
| 19018731 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING PSYCHIATRIC DISORDERS | January 2025 | March 2025 | Allow | 2 | 0 | 0 | Yes | No |
| 18964259 | USE OF CHIDAMIDE IN PREPARING DRUG FOR TREATING RENAL FIBROSIS | November 2024 | July 2025 | Allow | 8 | 1 | 1 | Yes | No |
| 18793674 | ENTHESIS HEALING | August 2024 | November 2025 | Allow | 16 | 1 | 1 | Yes | No |
| 18776438 | METHOD OF USING ILOPROST FOR TREATING FROSTBITE | July 2024 | July 2025 | Allow | 12 | 2 | 0 | Yes | No |
| 18764507 | SULFORAPHANE-CYSTEINE FOR WOUND HEALING IN DIABETIC SUBJECTS | July 2024 | November 2024 | Allow | 4 | 0 | 0 | Yes | No |
| 18375745 | PKC-ACTIVATING COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | October 2023 | April 2025 | Allow | 18 | 0 | 0 | Yes | No |
| 18264809 | OXADIAZOLYL DIHYDROPYRANO[2,3-b]PYRIDINE INHIBITORS OF HIPK2 FOR TREATING KIDNEY FIBROSIS | August 2023 | March 2026 | Allow | 31 | 1 | 0 | Yes | No |
| 18320159 | A19-144, A2-73 and Certain Anticholinesterase Inhibitor Compositions and Method for Anti-Seizure Therapy | May 2023 | December 2025 | Allow | 31 | 1 | 1 | Yes | No |
| 18320001 | OPTIMIZING VOLATILE ENTOURAGES IN DRY FLOWERING PLANT MIXTURES | May 2023 | January 2026 | Allow | 32 | 2 | 1 | No | No |
| 18311221 | USE OF CANNABINOIDS IN THE TREATMENT OF ANGELMAN SYNDROME | May 2023 | January 2026 | Allow | 32 | 1 | 0 | Yes | No |
| 18030853 | Phenyl-3,4-dihydroisoquinolin-2(1h)-yl-ethan-1-one derivatives as dopamine d1receptor positive allosteric modulators | April 2023 | October 2025 | Allow | 30 | 0 | 0 | Yes | No |
| 18180398 | MITOFUSIN ACTIVATORS AND METHODS OF USE THEREOF | March 2023 | May 2025 | Allow | 26 | 0 | 1 | Yes | No |
| 18024545 | AZETIDINYL TRYPTAMINES AND METHODS OF TREATING PSYCHIATRIC DISORDERS | March 2023 | August 2025 | Allow | 29 | 0 | 0 | Yes | No |
| 18178336 | METHODS FOR KILLING ANTIBIOTIC TOLERANT BACTERIA | March 2023 | July 2025 | Allow | 29 | 0 | 1 | Yes | No |
| 18170235 | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | February 2023 | September 2025 | Abandon | 31 | 1 | 0 | No | No |
| 18101499 | TREATMENT OF A HEMATOLOGIC MALIGNANCY WITH 2-(4-CHLOROPHENYL)-N-((2-(2,6- DIOXOPIPERIDIN-3-YL)-1-OXOISOINDOLIN-5-YL)METHYL)-2,2-DIFLUOROACETAMIDE | January 2023 | September 2025 | Abandon | 31 | 1 | 0 | No | No |
| 18005841 | USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO GENETIC ABNORMALITIES | January 2023 | March 2026 | Abandon | 38 | 1 | 0 | No | No |
| 18152616 | FFA1 (GPR40) AS A THERAPEUTIC TARGET FOR NEURAL ANGIOGENESIS DISEASES OR DISORDERS | January 2023 | September 2025 | Abandon | 32 | 0 | 1 | No | No |
| 18004658 | 1-[1-(4-BENZYLOXY-3,5-DIFLUORO-BENZOYL)-4-FLUORO-PYRROLIDINE-2-CARBONYL]-PYRROLIDINE-2-CARBONITRILE | January 2023 | July 2025 | Allow | 31 | 0 | 0 | Yes | No |
| 18083502 | COMPOSITION FOR PROMOTING NORMAL URINARY FUNCTION | December 2022 | February 2025 | Allow | 26 | 0 | 0 | Yes | No |
| 18064676 | COMPOSITIONS AND METHODS FOR TREATING ACNE VULGARIS | December 2022 | February 2026 | Abandon | 38 | 0 | 1 | No | No |
| 18009107 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR PORPHYRIA | December 2022 | March 2026 | Allow | 39 | 1 | 0 | No | No |
| 18009161 | Methods and Compositions for Treating Mild Traumatic Brain Injury, Post-Traumatic Stress Disorder and Mild Traumatic Brain Injury with Post Traumatic Stress Disorder | December 2022 | January 2026 | Abandon | 37 | 0 | 1 | No | No |
| 17984833 | ALPHA-AMINO ESTERS OF HYDROXYPROPYLTHIAZOLIDINE CARBOXAMIDE DERIVATIVE AND SALT FORM, CRYSTAL POLYMORPH THEREOF | November 2022 | July 2025 | Abandon | 32 | 1 | 0 | No | No |
| 17979670 | TREATMENT OF DISEASE WITH ESTERS OF SELECTIVE RXR AGONISTS | November 2022 | September 2025 | Abandon | 34 | 0 | 1 | No | No |
| 17979661 | TREATMENT OF DISEASE WITH ESTERS OF SELECTIVE RXR AGONISTS | November 2022 | September 2025 | Abandon | 34 | 0 | 1 | No | No |
| 17922767 | METHOD FOR TREATING CENTRAL NERVOUS SYSTEM DISORDERS USING DOPAMINE D3 PARTIAL AGONISTS | November 2022 | November 2025 | Allow | 37 | 1 | 0 | No | No |
| 17967676 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR NEUROPATHIC PAIN ASSOCIATED WITH GUILLAIN-BARRE SYNDROME | October 2022 | November 2024 | Abandon | 25 | 2 | 0 | No | No |
| 17967383 | PESTICIDAL COMPOSITIONS AND RELATED METHODS | October 2022 | May 2025 | Allow | 31 | 1 | 0 | No | No |
| 17914572 | COMPOSITIONS FOR TREATMENT OF AGED DISEASES | September 2022 | January 2026 | Abandon | 39 | 0 | 1 | No | No |
| 17818083 | COMPOSITION FOR TREATING HAIR LOSS OR PROMOTING HAIR GROWTH, COMPRISING PIPERONYLIC ACID | August 2022 | May 2025 | Allow | 33 | 0 | 0 | Yes | No |
| 17878121 | USE OF RILUZOLE, RILUZOLE PRODRUGS OR RILUZOLE ANALOGS WITH IMMUNOTHERAPIES TO TREAT CANCERS | August 2022 | July 2025 | Abandon | 36 | 2 | 0 | No | No |
| 17875679 | PHARMACEUTICAL COMPOSITION FOR REDUCING LOCAL FAT AND USES THEREOF | July 2022 | March 2025 | Allow | 31 | 0 | 0 | Yes | No |
| 17795609 | THERAPEUTIC AGENT FOR MYALGIC ENCEPHALOMYELITIS/CHRONIC FATIGUE SYNDROME | July 2022 | December 2025 | Allow | 40 | 1 | 0 | Yes | No |
| 17789876 | COMPOUND FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISORDERS | June 2022 | November 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17851395 | HYDROGEN CONTAINING COMPOSITION AND METHODS OF USING THE SAME | June 2022 | July 2025 | Abandon | 37 | 1 | 0 | No | No |
| 17788813 | USE OF A BENZODIAZEPINE DERIVATIVE AND METHOD OF TREATMENT OF TRAUMATIC BRAIN INJURY | June 2022 | November 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17788615 | USE OF LOSARTAN FOR THE TREATMENT OF FIBROTIC DISEASES, IN PARTICULAR EPIDERMOLYSIS BULLOSA | June 2022 | October 2025 | Allow | 40 | 1 | 0 | Yes | No |
| 17844715 | Methods for treating inflammatory skin conditions | June 2022 | January 2026 | Allow | 43 | 2 | 0 | No | No |
| 17832058 | CITRULLINE FOR TREATMENT OF SICKLE CELL CRISIS | June 2022 | February 2025 | Allow | 33 | 0 | 1 | Yes | No |
| 17782534 | USE OF FGFR INHIBITORS FOR TREATMENT OF IDIOPATHIC SHORT STATURE | June 2022 | May 2025 | Allow | 36 | 0 | 0 | Yes | No |
| 17830532 | 3-(5-CHLORO-2-OXOBENZO[D]OXAZOL-3(2H)-YL) PROPANOIC ACID DERIVATIVES AS KMO INHIBITORS | June 2022 | September 2025 | Allow | 40 | 0 | 1 | Yes | No |
| 17778802 | PROPHYLACTIC SKIN TREATMENT FOR RADIATION THERAPY | May 2022 | May 2025 | Allow | 35 | 0 | 0 | Yes | No |
| 17777677 | CANNABIDIOL-TYPE CANNABINOID COMPOUND | May 2022 | March 2025 | Allow | 34 | 0 | 0 | Yes | No |
| 17777734 | CANNABIDIOL-TYPE CANNABINOID COMPOUND | May 2022 | April 2025 | Allow | 35 | 0 | 0 | Yes | No |
| 17777681 | CANNABIDIOL-TYPE CANNABINOID COMPOUND | May 2022 | April 2025 | Allow | 35 | 0 | 0 | Yes | No |
| 17776222 | OLEIC ACID DERIVATIVES AS TREATMENTS FOR FRIEDREICH ATAXIA AND INHIBITORS OF FERROPTOSIS | May 2022 | March 2025 | Allow | 34 | 0 | 0 | Yes | No |
| 17639365 | FORMULATIONS AND TREATMENT METHODS | March 2022 | February 2026 | Allow | 47 | 1 | 1 | Yes | No |
| 17633811 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISEASE | February 2022 | January 2026 | Allow | 47 | 2 | 1 | No | No |
| 17667323 | NOVEL D3 DOPAMINE RECEPTOR AGONISTS TO TREAT DYSKINESIA IN PARKINSON'S DISEASE | February 2022 | August 2025 | Abandon | 42 | 1 | 1 | No | No |
| 17666324 | MORE POTENT AND LESS TOXIC FORMULATIONS OF EPINEPHRINE AND METHODS OF MEDICAL USE | February 2022 | December 2024 | Allow | 34 | 1 | 0 | No | No |
| 17568477 | TRIPLE COMBINATION FORMULATION FOR TREATMENT OF CHRONIC PAIN | January 2022 | December 2024 | Abandon | 35 | 3 | 1 | No | No |
| 17620670 | ANTIBACTERIAL AND ANTIPARASITIC QUINOXALINE-2,3-DIAMINE DERIVATIVES | December 2021 | August 2025 | Allow | 44 | 0 | 1 | Yes | No |
| 17305510 | COMPOSITIONS FOR PREVENTING AND TREATING DIABETES | July 2021 | January 2024 | Allow | 30 | 2 | 1 | Yes | No |
| 17359272 | COMPOSITION AND METHOD FOR TREATING AUTISM SPECTRUM DISORDER (ASD) SYMPTOMS OF PARANOIA WITH SELF ISOLATION AND/OR AGGRESSION | June 2021 | October 2024 | Allow | 40 | 2 | 1 | Yes | No |
| 17216756 | SELECTIVE ESTROGEN RECEPTOR MODULATOR FOR TREATMENT OF PANCREATIC CANCER | March 2021 | July 2025 | Abandon | 52 | 4 | 1 | No | No |
| 17180991 | METHODS OF TREATING IDIOPATHIC HYPERSOMNIA | February 2021 | September 2024 | Allow | 43 | 3 | 0 | No | No |
| 17172846 | Methods Of Treating Fabry Disease | February 2021 | November 2025 | Allow | 57 | 3 | 1 | No | No |
| 17128458 | USE OF CANNABIDIOLIC ACID IN THE TREATMENT OF AUTISM SPECTRUM DISORDER AND ASSOCIATED DISORDERS | December 2020 | July 2024 | Allow | 43 | 2 | 0 | Yes | No |
| 17099224 | ENTHESIS HEALING | November 2020 | June 2024 | Allow | 43 | 2 | 1 | Yes | No |
| 16648342 | Methods For Assessing Risk Of Cardiovascular Disease And Methods And Compounds For Use In Treating Or Preventing Cardiovascular Disease | March 2020 | January 2026 | Allow | 60 | 4 | 1 | Yes | No |
| 16523568 | METHOD FOR TREATING EPILEPSY | July 2019 | October 2025 | Allow | 60 | 5 | 1 | Yes | Yes |
| 16324353 | THERAPEUTIC AGENTS FOR NEURODEGENERATIVE DISEASES | February 2019 | September 2024 | Allow | 60 | 5 | 2 | Yes | Yes |
| 16239719 | TOPICAL FORMULATIONS OF PDE-4 INHIBITORS AND THEIR METHODS OF USE | January 2019 | March 2019 | Allow | 2 | 0 | 0 | No | No |
| 16310641 | COMPRESSED CAPSULES FOR GIVING BIRTH TO MALES | December 2018 | July 2019 | Allow | 6 | 0 | 0 | No | No |
| 16191243 | CHEMICAL MODULATORS OF IMMUNE CHECKPOINTS AND THERAPEUTIC USE | November 2018 | September 2019 | Allow | 11 | 0 | 1 | No | No |
| 16095282 | COMPOUNDS AND METHODS FOR TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | October 2018 | September 2024 | Allow | 60 | 2 | 1 | Yes | No |
| 16163108 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR NEUROPATHIC PAIN ASSOCIATED WITH GUILLAIN-BARRE SYNDROME | October 2018 | January 2025 | Abandon | 60 | 6 | 0 | No | Yes |
| 16112426 | GOLD COMPLEX-CONTAINING CANCER ACTIVITY COMPOSITION | August 2018 | February 2019 | Allow | 5 | 0 | 0 | No | No |
| 16111884 | MONONUCLEOTIDE-DITHIOCARBAMATE COMPLEX | August 2018 | January 2019 | Allow | 5 | 0 | 0 | No | No |
| 16112358 | CANCER CELL-CONTAINING COMPOSITION | August 2018 | January 2019 | Allow | 4 | 0 | 0 | No | No |
| 16112188 | DNA/DITHIOCARBAMATO PHOSPHINE METAL COMPLEX | August 2018 | February 2019 | Allow | 6 | 0 | 0 | No | No |
| 16107087 | ARGINASE INHIBITORS AS THERAPEUTICS | August 2018 | November 2019 | Allow | 15 | 1 | 0 | No | No |
| 15993163 | GOLD COMPLEXES OF ALKYLATED PHOSPHINES | May 2018 | August 2018 | Allow | 2 | 0 | 0 | No | No |
| 15990289 | COMPOSITION CONTAINING A GOLD (I) COMPLEX AND CANCER CELLS | May 2018 | August 2018 | Allow | 3 | 0 | 0 | No | No |
| 15952875 | CANNABIS-BASED THERAPEUTIC PRODUCT FOR TREATMENT OF CHRONIC PAIN | April 2018 | November 2018 | Allow | 7 | 1 | 0 | No | No |
| 15767756 | C-3 NOVEL TRITERPENONE WITH C-28 UREA DERIVATIVES AS HIV INHIBITORS | April 2018 | January 2020 | Allow | 21 | 1 | 0 | Yes | No |
| 15951154 | ENHANCED SMOKABLE THERAPEUTIC CANNABIS PRODUCT AND METHOD FOR MAKING SAME | April 2018 | November 2018 | Allow | 7 | 1 | 0 | No | No |
| 15904265 | ISOQUINOLIDINOBENZODIAZEPINE (IQB)-1(CHLOROMETHYL)-2,3-DIHYDRO-1H-BENZO[E]INDOLE (CBI) DIMERS | February 2018 | March 2019 | Allow | 12 | 1 | 1 | No | No |
| 15783510 | METHODS AND COMPOSITIONS FOR TREATING PAIN | October 2017 | March 2019 | Allow | 17 | 1 | 0 | No | No |
| 15680819 | MEDICAMENT FOR THE TREATMENT OF VIRAL SKIN AND TUMOUR DISEASES | August 2017 | July 2019 | Allow | 22 | 1 | 1 | No | No |
| 15449723 | NOVEL CHOLINE COCRYSTAL OF EPALRESTAT | March 2017 | June 2019 | Allow | 28 | 3 | 1 | Yes | No |
| 15432616 | 1,3-Dihydroimidazole-2-Thione Derivatives for Use in the Treatment of Pulmonary Arterial Hypertension and Lung Injury | February 2017 | January 2019 | Allow | 23 | 1 | 1 | No | No |
| 15328304 | CURCUMIN-SOPHOROLIPID COMPLEX | January 2017 | December 2017 | Allow | 11 | 0 | 1 | Yes | No |
| 15385248 | METHODS OF TREATING LIVER DISEASES | December 2016 | April 2018 | Allow | 16 | 1 | 0 | No | No |
| 15383245 | PYRAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | December 2016 | December 2017 | Allow | 12 | 0 | 1 | No | No |
| 15351585 | MIXED LIGAND GOLD(I) COMPLEXES AS ANTI-CANCER AGENTS | November 2016 | May 2018 | Allow | 18 | 1 | 2 | No | No |
| 15301127 | PYRIDAZIN-3(2H)-ONE DERIVATIVES AS MONOAMINE OXIDASE SELECTIVE ISOFORM B INHIBITORS (As Amended) | September 2016 | November 2018 | Allow | 26 | 0 | 1 | No | No |
| 15076004 | COMPOSITIONS AND METHODS FOR TREATING BACTERIAL INFECTIONS | March 2016 | December 2016 | Allow | 8 | 0 | 0 | No | No |
| 14780239 | INFANT FORMULA WITH A LOW CONTENT OF MCFAS IN SPECIFIC PROPORTIONS AND A RELATIVELY HIGH CONTENT OF UNSATURATED FATTY ACIDS, AND ITS USE IN PROMOTING THE HEALTHY ESTABLISHMENT OF COGNITIVE FUNCTION IN INFANTS | September 2015 | August 2017 | Allow | 22 | 2 | 1 | No | No |
| 14758724 | CYP450 Lipid Metabolites Reduce Inflammation and Angiogenesis | June 2015 | May 2017 | Allow | 23 | 2 | 1 | Yes | No |
| 14649272 | USE OF CAPSAZEPINE AND ANALOGS THEREOF TO TREAT CANCER | June 2015 | September 2016 | Allow | 15 | 1 | 0 | No | No |
| 14647740 | USE AND APPLICATION REGIMEN OF A PHARMACEUTICAL COMPOSITION CONTAINING LEVONORGESTREL AND A COX INHIBITOR FOR ON-DEMAND CONTRACEPTION | May 2015 | November 2016 | Allow | 18 | 1 | 1 | No | No |
| 14647633 | POWDEROUS FORMULATION | May 2015 | October 2017 | Allow | 29 | 3 | 0 | No | Yes |
| 14440724 | METHODS OF TREATING LIVER DISEASES | May 2015 | September 2016 | Allow | 17 | 1 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner JAVANMARD, SAHAR.
With a 66.7% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 46.2% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner JAVANMARD, SAHAR works in Art Unit 1622 and has examined 159 patent applications in our dataset. With an allowance rate of 98.1%, this examiner allows applications at a higher rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 34 months.
Examiner JAVANMARD, SAHAR's allowance rate of 98.1% places them in the 90% percentile among all USPTO examiners. This examiner is more likely to allow applications than most examiners at the USPTO.
On average, applications examined by JAVANMARD, SAHAR receive 1.73 office actions before reaching final disposition. This places the examiner in the 37% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by JAVANMARD, SAHAR is 34 months. This places the examiner in the 42% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +3.3% benefit to allowance rate for applications examined by JAVANMARD, SAHAR. This interview benefit is in the 25% percentile among all examiners. Recommendation: Interviews provide a below-average benefit with this examiner.
When applicants file an RCE with this examiner, 37.1% of applications are subsequently allowed. This success rate is in the 84% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 58.1% of cases where such amendments are filed. This entry rate is in the 84% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 100.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 69% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 78.6% of appeals filed. This is in the 70% percentile among all examiners. Of these withdrawals, 72.7% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 46.2% are granted (fully or in part). This grant rate is in the 40% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.
Examiner's Amendments: This examiner makes examiner's amendments in 15.1% of allowed cases (in the 97% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.